Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Jilin ZC New Materials is a high-tech biotechnology company based in China that specializes in the research, development, and production of bioactive glass and regenerative biomaterials. The company's core technology centers on bioactive glass, which is utilized in a variety of medical applications including orthopedic bone repair, dental reconstruction, and advanced wound care. Their flagship products include synthetic bone graft substitutes and bioactive glass-based ointments that facilitate tissue regeneration and provide antimicrobial properties. Jilin ZC New Materials serves the clinical market by providing high-performance materials for complex surgeries and chronic wound management. The company maintains a strong focus on innovation within the field of regenerative medicine and holds multiple patents for its proprietary material formulations.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Jilin ZC New Materials.